National Institute on Drug Abuse; Notice of Closed Meetings, 12858 [2012-5039]
Download as PDF
<![CDATA[
12858
Federal Register / Vol. 77, No. 42 / Friday, March 2, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel NIDA–
K Special Emphasis Panel (SEP).
Date: March 6, 2012.
Time: 4:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Nadine Rogers, Ph.D.,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4229, MSC 9550, Bethesda, MD
20892–9550, 301–402–2105,
rogersn2@nida.nih.gov
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel,
Collaborative Clinical Trials in Drug Abuse.
Date: March 13, 2012.
Time: 11 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4238, MSC 9550, Bethesda, MD
20892–9550, 301–402–6626,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel,
Multisite Medications Development for
SUDs.
Date: March 15, 2012.
Time: 11 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
VerDate Mar<15>2010
17:01 Mar 01, 2012
Jkt 226001
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4238, MSC 9550, Bethesda, MD
20892–9550, 301–402–6626,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, 2012
Translational Avant Garde Review (DP1).
Date: March 27, 2012.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn, 7301 Waverly
Street, Bethesda, MD 20814.
Contact Person: Scott A. Chen, Ph.D.,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4234, MSC
9550, 6001 Executive Blvd., Bethesda, MD
20892–9550, 301–443–9511,
chensc@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, DIDARP
Review.
Date: March 30, 2012.
Time: 12 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nadine Rogers, Ph.D.,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4229, MSC 9550, Bethesda, MD
20892–9550, 301–402–2105,
rogersn2@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 24, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–5039 Filed 3–1–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Cell Biology.
Date: March 21–22, 2012.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Wallace Ip, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5128,
MSC 7840, Bethesda, MD 20892, 301–435–
1191, ipws@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, RFA Panel:
CounterAct U54 Cooperative Agreements.
Date: March 22, 2012.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Alexandria, 480 King
Street, Alexandria, VA 22314.
Contact Person: Jonathan K Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040A,
MSC 7806, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Fellowship:
Oncological Sciences.
Date: March 22–27, 2012.
Time: 11 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Ross D Shonat, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5156,
MSC 7849, Bethesda, MD 20892, 301–435–
2786, shonatr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, RFA Panel:
CounterAct U01 Cooperative Agreements.
Date: March 23, 2012.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Alexandria, 480 King
Street, Alexandria, VA 22314.
Contact Person: Jonathan K Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040A,
MSC 7806, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, RFA MH12–
080: Advancing HIV Prevention through
Transformative Behavioral and Social
Science Research.
Date: March 23, 2012.
E:\FR\FM\02MRN1.SGM
02MRN1
]]>Agencies
[Federal Register Volume 77, Number 42 (Friday, March 2, 2012)]
[Notices]
[Page 12858]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-5039]
[[Page 12858]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
USC, as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
.Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel NIDA-K Special Emphasis Panel (SEP).
Date: March 6, 2012.
Time: 4:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW., Washington, DC 20015.
Contact Person: Nadine Rogers, Ph.D., Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550,
Bethesda, MD 20892-9550, 301-402-2105, rogersn2@nida.nih.gov
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel, Collaborative Clinical Trials in Drug Abuse.
Date: March 13, 2012.
Time: 11 a.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel, Multisite Medications Development for SUDs.
Date: March 15, 2012.
Time: 11 a.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel, 2012 Translational Avant Garde Review (DP1).
Date: March 27, 2012.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn, 7301 Waverly Street, Bethesda, MD
20814.
Contact Person: Scott A. Chen, Ph.D., Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd.,
Bethesda, MD 20892-9550, 301-443-9511, chensc@mail.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel, DIDARP Review.
Date: March 30, 2012.
Time: 12 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Nadine Rogers, Ph.D., Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550,
Bethesda, MD 20892-9550, 301-402-2105, rogersn2@nida.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279,
Drug Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: February 24, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-5039 Filed 3-1-12; 8:45 am]
BILLING CODE 4140-01-P
